Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | TACR3 | P29371 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29609212 | 1.00 | HDAC9 (0.45) | HDAC9HCAR2TACR1TACR3TSHR | |
| SCHEMBL2599391 | 0.90 | AKR1C1 (0.43) | HDAC9TSHRSIGMAR1TP53CYP1A2 | |
| SCHEMBL29609235 | 0.90 | AKR1C1 (0.43) | HDAC9TSHRSIGMAR1TP53CYP1A2 | |
| SCHEMBL6751391 | 0.85 | HDAC9 (0.44) | HDAC9HCAR2TACR1TACR3TSHR | |
| SCHEMBL16116728 | 0.85 | HDAC9 (0.44) | HDAC9HCAR2TACR1TACR3TSHR | |
| SCHEMBL1153942 | 0.83 | TACR3 (0.53) | HDAC9HCAR2TACR1TACR3TSHR | |
| SCHEMBL16075939 | 0.81 | TACR3 (0.44) | HDAC9HCAR2TACR1TACR3KIF11 | |
| SCHEMBL28940851 | 0.79 | MMP8 (0.49) | HDAC9TACR1TACR3TSHR | |
| SCHEMBL21777572 | 0.79 | KDM1A (0.43) | TACR1TACR3KDM1A | |
| SCHEMBL18088634 | 0.79 | HDAC9 (0.40) | HDAC9HCAR2TACR1TACR3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| WO-2022109741-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-06-02 | — | — | WO | disclosed |
| CN-114539340-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2020151707-A1 | NOVEL SMALL MOLECULE CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2020-07-30 | — | — | WO | disclosed |
| EP-2571860-A1 | 2-PHENYL BENZOYLAMIDES | Pfizer Inc (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | HDAC9 1617/4885HCAR2 1403/4885TACR1 2063/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | HDAC9 1617/4885HCAR2 1403/4885TACR1 2063/4885 |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | APOB, MTTP, HADHB | HDAC9 2334/4885HCAR2 2123/4885TACR1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.